Stockscreener 앱 받기
1.59
1.92%
0.03
시간 외 거래:
1.59
Repare Therapeutics Inc 주식(RPTX)의 최신 뉴스
Repare Therapeutics (NASDAQ:RPTX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Candlestick Reversal Detected on Repare Therapeutics Inc.’s ChartScalable Portfolio Growth Suggestions Released - 선데이타임즈
Is Repare Therapeutics Inc. still worth holding after the dipFree Risk-Adjusted Picks With Exit Strategy - Newser
Using portfolio simulators with Repare Therapeutics Inc. includedSafe Investment Ideas with Growth Upside - Newser
Repare Therapeutics (NASDAQ:RPTX) Issues Quarterly Earnings Results - MarketBeat
Is Repare Therapeutics Inc. forming a reversal patternFree Market Surge Signal for Swing Traders - Newser
Backtesting results for Repare Therapeutics Inc. trading strategiesPattern Recognition Based Market Move Prediction - Newser
Is Repare Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSafe Momentum Strategy With Trend Analysis - Newser
Repare Therapeutics Q2 2025 Earnings: EPS Beats Estimates, Revenue Surpasses Expectations - AInvest
Repare Therapeutics Inc (RPTX) Q2 2025 Earnings: EPS of -$0.39 B - GuruFocus
Will Repare Therapeutics Inc. benefit from macro trendsDay Trading Plan with Entry Risk Management - Newser
Analyzing recovery setups for Repare Therapeutics Inc. investorsFree Smart Trend Trading with Weekly Signals - Newser
Repare Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Repare Therapeutics Reports Q2 2025 Results and Strategic Moves - TipRanks
Repare Therapeutics Reports Q2 Earnings: Strategic Moves and Upcoming Data Releases - AInvest
Repare Therapeutics Announces Licensing Deal and Strategic Updates - The Globe and Mail
Repare 2025 Q2 Earnings Strong Improvement as Net Loss Narrows 51.8% - AInvest
Repare Therapeutics Cuts Losses And Snags New Licensing Deals - Finimize
Repare Therapeutics Narrows Losses And Seeks New Paths Forward - Finimize
Repare (RPTX) Q2 Loss Narrows 52% - AOL.com
Repare Therapeutics' Strategic Shift and Milestone-Driven Outlook - AInvest
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year - TipRanks
Repare Therapeutics Inc. SEC 10-Q Report - TradingView
Repare Therapeutics Q2 net loss narrows to $16.7 mln - MarketScreener
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results | RPTX Stock News - GuruFocus
Repare Therapeutics reports Q2 2025 revenue $109.5 mln, cash & marketable securities. - AInvest
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - The Globe and Mail
Predicting Repare Therapeutics Inc. trend using moving averagesChart Scanner for Swing Trade Timing - Newser
Repare Therapeutics Provides Business Update and Reports Second - GuruFocus
Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Daily Profit Focused Stock Screener - Newser
Can Repare Therapeutics Inc. hit a new high this monthFree Low Risk Swing Trade Opportunity List - Newser
Quantitative breakdown of Repare Therapeutics Inc. recent movePredicted Market Direction Based on Momentum - Newser
What makes Repare Therapeutics Inc. stock price move sharplyUnlock market-leading stock analysis - Jammu Links News
Should I hold or sell Repare Therapeutics Inc. stock in 2025Maximize gains with proven stock analysis - Jammu Links News
Repare Therapeutics Inc. Stock Analysis and ForecastAchieve rapid wealth accumulation with smart picks - Jammu Links News
How volatile is Repare Therapeutics Inc. stock compared to the marketMaximize portfolio value with smart investment plans - Jammu Links News
When is Repare Therapeutics Inc. stock expected to show significant growthAmplify your gains with low-risk picks - Jammu Links News
Does Repare Therapeutics Inc. stock perform well during market downturnsMaximize returns with data-driven strategies - Jammu Links News
Is Repare Therapeutics Inc. a growth stock or a value stockUnlock your portfolio’s hidden potential - Jammu Links News
How many analysts rate Repare Therapeutics Inc. as a “Buy”Capitalize on momentum stocks before they peak - Jammu Links News
1.67%
자본화:
|
볼륨(24시간):